Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Onfasprodil SCHEMBL30648114 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL17633369 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL29346467 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL29882782 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL20086359 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL17633403 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL17633258 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL30648127 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL17633362 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B | |
| Onfasprodil SCHEMBL20983421 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2025120013-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2025-06-12 | — | — | WO | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4649143-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | Novartis AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025120013-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025120013-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2025-06-12 | — | — | WO | disclosed |
| EP-4531851-A1 | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS | Novartis AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| EP-4531851-A1 | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS | Novartis AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-119654149-A | Subcutaneous administration and dosing method of olanzapine for use in the treatment of depressive disorders | 诺华股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024150146-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | NOVARTIS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023233357-A1 | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023233357-A1 | SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS | NOVARTIS AG (CH) | 2023-12-07 | — | — | WO | disclosed |